Maruho
Privately held: no public share price
Assets
(3 total)
3Total Assets
2Approved
0Phase 3 / Filed
1Phase 1–2 / Early
6Diseases
Quick filter:
| Target & Modality | |||
|---|---|---|---|
nemolizumab(Nemluvio) | Approved | IL-31 receptor AMonoclonal antibody | Atopic DermatitisPrurigo Nodularis |
| Approved | JAK1/2Small molecule | Atopic DermatitisPrurigo NodularisVitiligoHidradenitis Suppurativa | |
| Phase 2 | MRGPRX2Small molecule | MigraineUrticaria Chronic Inducible Urticaria |
Upcoming events
(7 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2026 (1)
December 2026 (1)
Est. primary completion 2026-12 · NCT07074977 · CT.gov ↗
What to watch
2027 (3)
Regulatory and conference events
(4)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
8 September 2026Topline resultEVO756Phase 2b of EVO756 in atopic dermatitis did not meet its primary endpoint
Evommune · Source ↗
29 July 2026ApprovalRuxolitinib (Opzelura)European Commission approves Opzelura cream for moderate atopic dermatitis
EU, EC · Source ↗
29 June 2026Topline resultEVO756Phase 2b of EVO756 in chronic spontaneous urticaria did not meet its primary endpoint
Evommune · Source ↗
Financial reports
No financial reports recorded.